Thanks to the application of sophisticated data integration techniques and state of the art artificial intelligence (AI) methodologies, we recently completed the creation of our comprehensive biological Target Database, with the aim to accelerate drug discovery processes. By integration, collation and normalization of data from various validated datasets and sources, we provide a unique repository of information essential for researchers and pharmaceutical companies. In particular, the incorporation of over 6,000 human targets underscores the depth and breadth of insights available by using our platform.

IDM Insight aims to revolutionize drug discovery campaigns and market access strategies with our bespoke Prior Art service, changing the way data are accessed, analysed, and exploited, supporting researchers and professionals in making right decisions and propel their projects forward with confidence. Using the fully integrated and interconnected data already included in our meticulously developed database platform, we can provide unparalleled depth of information from regulatory requirements, clinical trials, biological targets and associated diseases to chemical compounds and known drugs. This wealth of data will be delivered conveniently and consistently in reports formats ready for any research, strategy or submission needs.

In the realm of healthcare and biomedical research, the rapid growth of information has paved the way for innovative approaches to understanding, treating, and preventing diseases. The significance of databases in the context of disease, pharmacology, and drug discovery lies in their ability to organize vast amounts of information in a structured and accessible manner. Data-driven insights derived from these databases empower researchers to make informed decisions and drive scientific advancements.

We're hosting a special launch webinar to showcase these new features. Not only will this be a chance to see them in action, but it's also an opportunity for you to ask questions and gain deeper insights.

Unlocking the potential of Artificial Intelligence (AI) in healthcare has yielded remarkable quantitative results. Let's explore the data-driven impact of AI, revolutionizing patient care and outcomes.

Harnessing the Potential of Data: The process of developing a new drug involves numerous complex steps, each requiring meticulous analysis and evaluation. Traditionally, drug developers have faced significant challenges in accessing, collating, and analyzing diverse datasets that span across various domains. However, IDM's Insight serves as a game-changer, providing a centralized platform that consolidates and organizes these crucial datasets, enabling developers to tap into the full potential of data-driven insights.

Discover how Insight, our intelligence platform, can help you navigate the complex regulatory landscape and avoid costly noncompliance consequences like form 483 and warning letters. In the pharmaceutical industry, the process of developing and bringing a new drug to market can be a lengthy and expensive endeavor. In fact, the cost of developing a new drug can reach as much as $2.6 billion, making every day of delay in the drug development process cost up to a million dollars. This cost can add up quickly, making it crucial to avoid delays wherever possible.

Stay Informed on Ongoing Trials: With the Insight platform, you'll stay up to date on the progress, patient outcomes, and safety profiles of ongoing mRNA vaccine trials. By staying informed, you can identify collaboration opportunities, leverage trial results, and refine your research strategies to accelerate progress.

Discover how the innovative alert functionality of IDM’s Insight platform can keep you up to date with the latest advancements in clinical trials, giving you a competitive edge